Understanding the Cost Effectiveness of COVID-19 Vaccination in Nigeria
Ouvert
- Détails du fichier
- Size: 25MB
- Créateur / Auteur : Joan Addedis
- Type de ressource : Africa Capacity Report
- # Télécharger: 254
- Accéder: Open to Download
Télécharger des fichiers
understanding-cost-effectiveness-covid-19-vaccination-nigeria.pdf
Informations de base
Créateur / Auteur
Benjamin S.C. Uzochukwu, Chinyere Okeke, Sergio Torres-Rueda, Carl Pearson, Eleanor Bergren, Anthony McDonnell, Anna Vassall, Mark Jit, Francis Ruiz
Nombre de pages
6
Détails géographiques et d'audience
Classification et domaines
Objet
COVID-19, Vaccines, Africa, Global Health
Résumé
COVID-19 has disrupted health systems across the globe. Nigeria reported its first COVID-19 case in February 2020, and, since then, the government has rolled out four vaccines to help control the pandemicModerna, Oxford-Astra Zeneca (AZ), Johnson & Johnson (J&J) and Pfizer-BioNTech. Nigeria set an ambitious goal of vaccinating 40 percent of its over 200 million people before the end of 2021, and 70 percent by the end of 2022. The vaccine rollout was organised into four phases, as shown in table 1. Access to vaccines in Nigeria has been limited, however, and vaccine hesitancy has further slowed down deployment. There is also limited evidence on the comparative clinical and cost-effectiveness of COVID-19 interventionsincluding vaccinationin the Nigerian context specifically.
Connexion requise
Veuillez vous connecter ou créer un compte pour consulter et publier des commentaires.
Se connecter S'inscrire